

RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)

Milan, 25th March 2021 – Please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 18th March 2021:

- (i) the **2020 Corporate Governance Report and Ownership Structure** pursuant to article 123-bis of Italian Legislative Decree no. 58 of 24th February 1998;
- (ii) the **Report on the Remuneration Policy and the remuneration paid** pursuant to article 123-ter, paragraphs 3-bis and 6, of Italian Legislative Decree no. 58 of 24th February 1998;
- (iii) the **Directors' Report relating to item no. 2 (Report on the Remuneration Policy and the remuneration paid)** of the agenda of the Ordinary Shareholders' Meeting called for 20th April 2021, which again includes, as its annex, the Report on the Remuneration Policy and the remuneration paid referred to in point (ii),

are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it, the first report in the Corporate Governance – Report on Corporate Governance and the Ownership Structure section; the second report in the Corporate Governance – Remuneration section; and the third report in the Investors - Shareholders' Meeting section) and on the '1INFO' storage mechanism (www.1info.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Federica De Medici
(39) 02 48787146
e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano
(39) 02 76004736, (39) 02 76004745
e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**Registered Office**

Via Matteo Civitali, 1
20148 Milano, Italy
Ph. (39) 02 487871
Fax (39) 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832